FibroBiologics' (FBLG) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of FibroBiologics (NASDAQ:FBLG - Free Report) in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a $12.00 target price on the stock.

FBLG has been the topic of a number of other reports. EF Hutton Acquisition Co. I raised FibroBiologics to a "strong-buy" rating in a research report on Wednesday, September 4th. Maxim Group started coverage on FibroBiologics in a research report on Tuesday, September 24th. They set a "buy" rating and a $12.00 price target on the stock.

FibroBiologics Trading Down 0.3 %

FBLG traded down $0.01 on Wednesday, hitting $3.16. The company had a trading volume of 148,344 shares, compared to its average volume of 258,588. FibroBiologics has a 12-month low of $1.08 and a 12-month high of $55.00. The business's fifty day simple moving average is $2.94 and its 200 day simple moving average is $5.05.

Hedge Funds Weigh In On FibroBiologics

Several hedge funds have recently made changes to their positions in FBLG. Fund Evaluation Group LLC acquired a new position in shares of FibroBiologics during the 2nd quarter worth about $5,265,000. Cascade Financial Partners LLC purchased a new stake in shares of FibroBiologics in the second quarter valued at about $1,572,000. ERn Financial LLC purchased a new position in FibroBiologics during the second quarter worth about $159,000. Bank of New York Mellon Corp purchased a new position in FibroBiologics during the second quarter worth about $342,000. Finally, Mercer Global Advisors Inc. ADV purchased a new position in FibroBiologics during the second quarter worth about $51,000.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.